PGNY — Progyny, Inc.

Progyny Inc. (PGNY) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.29 billion for 2025, exceeding guidance by nearly $90 million.
• Adjusted EBITDA: $222 million, surpassing initial guidance by approximately $28 million.
• Operating Cash Flow: Record $210 million, a 17% increase from 2024.
• Fourth Quarter Revenue Growth: 7% year-over-year; 21% growth when excluding a large former client from 2024.
• Gross Margin: Expanded nearly 200 basis points for the full year.
• Stock-Based Compensation: Increased by $7.7 million due to the accelerated vesting of equity awards following the departure of the President.

2. Strategic Updates and Business Highlights

• Client Retention: Nearly 100% retention rate, including all major employers.
• Service Expansion: 30% of clients expanded their benefits with Progyny for 2026, adding access for over 2.7 million members to new services in pregnancy, postpartum, and menopause.
• Market Diversification: No single client accounts for more than a single-digit percentage of revenue, and no industry comprises more than 15% of lives.
• Progyny Select: New offering targeting smaller employers with a fixed premium model, expected to launch in 2026 but anticipated to contribute financially in 2027.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $1.355 billion and $1.405 billion, reflecting growth of 5.1% to 9%.
• Adjusted EBITDA for 2026: Expected between $224 million and $239 million.
• First Quarter 2026 Revenue Guidance: Anticipated between $319 million and $332 million, indicating a slight decline to modest growth compared to the previous year.
• Covered Lives: Expected to be 7.2 million in 2026, lower than previous estimates due to administrative adjustments from existing clients.

4. Bad News, Challenges, or Points of Concern

• Membership Outlook: A reduction of 400,000 covered lives attributed to administrative changes among existing clients, raising concerns about potential overstatements in previous membership figures.
• Stock-Based Compensation Impact: The unexpected increase in stock-based compensation due to executive departures could affect net income and earnings.
• Market Uncertainty: While the company has not seen pushback from employers regarding its services, there are ongoing macroeconomic uncertainties that could impact future performance.

5. Notable Q&A Insights

• Membership Changes: The delta in covered lives primarily affected existing clients, not new ones, and is attributed to administrative updates rather than workforce reductions.
• Progyny Rx Model: No significant pushback from employers regarding the model, which includes rebates at point of sale, and the economics are expected to remain stable despite potential changes in structure.
• Utilization Trends: The new cohort of clients is expected to drive higher utilization rates, particularly in ART cycles, contributing positively to future revenue.
• Sales Pipeline: Early selling season results are promising, with several wins already secured, although these are mostly from smaller clients rather than large employers.

This summary encapsulates the key elements of Progyny's Q4 2025 earnings call, providing a balanced view of the company's performance, strategic direction, and potential challenges ahead.